FMC Curporation

1735 Market Street Philadelphia Pennsylvania 19103 215 299 6000



11/28/95

ORIGINAL

## **CERTIFIED MAIL** RETURN RECEIPT REQUESTED

November 22, 1995

FMC



**Document Processing Center (7407)** Office of Pollution Prevention and Toxics 8EHQ\_ 1195\_ 13549 401 M Street, S.W. Washington, D.C. 20460

ATTN: TSCA 8(e) Coordinator

Dear Sir or Madam:

This notification is submitted on behalf of FMC Corporation ("FMC"), 1735 Market Street, Philadelphia, PA 19103, pursuant to Section 8(e) of the Toxic Substances Control Act, Public Law 94-469 ("TSCA") and the Statement of Interpretation and Enforcement Policy, 43 FR 11110-11116, March 16, 1978 (the "Policy Statement").

FMC has just received preliminary, unaudited results from a 1-Generation Reproduction Study in rats conducted with Hydroxyphosphonoacetic acid, CAS Registry Number 23783-26-8.

Dose levels of 0, 1, 10, 50, 150 and 500 mg/kg/day for this reproduction study were selected based on a 90-day oral gavage study. In the 90-day study the dose levels were 0, 20, 110 and 600 mg/kg/day. There were 10 animals/sex/ group. No females died during the course of the study. Among the males, 120 at 20 mg/kg and 3/10 at 600 mg/kg died.

In this oral gavage reproduction study rats are dosed for 10 weeks prior to mating. A summary of the mortality seen thus far:

| Dose Group (mg/kg/day)   | <u>0</u> | 1  | <u>10</u> | <u>50</u> | <u>150</u> | <u>500</u> |  |
|--------------------------|----------|----|-----------|-----------|------------|------------|--|
| Number of males in study | 24       | 24 | 24        | 24        | 24         | 24         |  |
| Number males dead        | 0        | 0  | 0         | 0         | 0          | 4          |  |
| Number females paired    | 24       | 24 | 24        | 24        | 24         | 23         |  |
| Number females dead      | 0        | 0  | 0         | 0         | 3          | 11         |  |

Most of the pregnant dams died within a matter of days of parturition. Because this level of mortality in the females was unexpected based on the similar length of treatment and dose levels in the 90-day study, FMC is submitting this information to EPA pursuant to TSCA 8(e).

FMC is making no claims of confidentiality for this submission.

A complete copy of the audited final report will be submitted to the Agency once it becomes available.

Sincerely yours,

Sinda Mclark

Linda M. Clark

Supervisor, Product Regulatory Affairs

215/299-6133

55 NOV 28 AHH: 1.1